Barclays PLC Reduces Holdings in Charles River Laboratories International, Inc. $CRL

2026-03-12 22:00:56

Barclays PLC significantly reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 15.9% in the third quarter, selling 28,519 shares and holding 151,359 shares valued at $23.68 million. Despite this reduction, other institutional investors have either increased their holdings or initiated new positions in the medical research company. Charles River Laboratories International reported strong quarterly earnings, beating analyst estimates, and currently holds a “Moderate Buy” rating from analysts with an average target price of $203.57.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.